Catalogo dei prodotti della ricerca

SERRAO, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.147
EU - Europa 473
AS - Asia 300
AF - Africa 19
SA - Sud America 4
OC - Oceania 2
Totale 2.945
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.131
IT - Italia 160
SG - Singapore 149
SE - Svezia 108
IN - India 92
CN - Cina 39
DE - Germania 37
BG - Bulgaria 36
FI - Finlandia 31
RO - Romania 22
UA - Ucraina 21
TG - Togo 17
GB - Regno Unito 14
CA - Canada 11
IE - Irlanda 9
CH - Svizzera 8
BE - Belgio 7
ID - Indonesia 7
NL - Olanda 6
HK - Hong Kong 5
MX - Messico 4
PL - Polonia 3
AR - Argentina 2
DK - Danimarca 2
FR - Francia 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BJ - Benin 1
CO - Colombia 1
CZ - Repubblica Ceca 1
ES - Italia 1
IS - Islanda 1
JO - Giordania 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LV - Lettonia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
RS - Serbia 1
SA - Arabia Saudita 1
SC - Seychelles 1
Totale 2.945
Salva come PNG Salva come JPEG
Città #
Fairfield 393
Ashburn 181
Seattle 175
Woodbridge 173
Houston 166
Chandler 147
Cambridge 133
Wilmington 126
Singapore 117
Ann Arbor 71
San Paolo di Civitate 56
Princeton 52
Millbury 47
Rome 41
Lawrence 38
Sofia 36
San Diego 30
Plano 28
Santa Clara 27
Bremen 25
Lomé 17
Andover 16
Beijing 16
Bologna 14
Boston 12
Trento 12
Dublin 9
Norwalk 9
New York 8
Brussels 7
Jakarta 7
Toronto 7
Jacksonville 6
Bern 5
Boardman 5
Des Moines 5
Hong Kong 5
London 5
Dearborn 4
Mexico City 4
Milan 4
Ottawa 4
Buffalo 3
Frankfurt am Main 3
Redwood City 3
Albino 2
Auburn Hills 2
Bratislava 2
Bühl 2
Federal 2
Helsinki 2
Kunming 2
Lappeenranta 2
Padova 2
Piano di Sorrento 2
Pozzuoli 2
Rovereto 2
Salisbury 2
San Mateo 2
Almaty 1
Amman 1
Amsterdam 1
Angers 1
Baku 1
Barcelona 1
Belgrade 1
Bishkek 1
Brescia 1
Cagliari 1
Copenhagen 1
Dubai 1
Edinburgh 1
Falkenstein 1
Fasano 1
Guangzhou 1
Hanover 1
Hounslow 1
Hyderabad 1
Keflavik 1
Laurel 1
Lima 1
Lincoln 1
Lodz 1
Mahé 1
Mannheim 1
Medellín 1
New Haven 1
Nuremberg 1
Paris 1
Parma 1
Phoenix 1
Prague 1
Pune 1
Riga 1
Riyadh 1
Shenyang 1
Shenzhen 1
Stockholm 1
Tauranga 1
Trumbull 1
Totale 2.321
Salva come PNG Salva come JPEG
Nome #
Azacitidine Followed by Radiotherapy as Effective Treatment for Chronic Myelomonocytic Leukemia with Extramedullary Localization. 109
Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma 100
MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine 96
Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib. 93
Use of edoxaban for the treatment of venous thromboembolism in HIV-infected patients 81
Combination of azacitidine and ESA in myelodysplastic patients: The need for prospective studies 79
5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. 78
The degree of anemia has an impact on survival in myelodysplastic syndrome patients classified with WPSS. 77
Current and future therapeutic approaches for the treatment of follicular lymphoma 76
Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase. 73
Azacitidine as salvage therapy in elderly patients with relapsed acute myeloid leukemia after autologous transplantation. 71
Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve? 71
Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response 70
Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes. 69
Direct oral anticoagulants in patients affected by major congenital thrombophilia 67
Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes. 66
. BEAM vs FEAM conditioning: retrospective study in lymphoma patients undergoing autologous stem cell transplant. 66
Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia. 66
Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib. 65
Long-term response to daratumumab in a patient with advanced immunoglobulin light-chain (AL) amyloidosis with organ damage 65
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population. 65
Antithrombin concentrate during pregnancy in congenital antithrombin deficiency: A single-center experience 64
Neutropenia at baseline could indicate poor prognosis in low/intermediate risk myelodysplastic syndrome patients 62
Nivolumab as a safe and effective treatment in an HIV patient with refractory Hodgkin lymphoma 62
Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors 62
Response to interferon-free direct antivirals (DAAS) treatment in Hcv-related subcutaneous marginal zone B-cell lymphoma with lipoma-like presentation: report of two cases 61
Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences. 61
Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index. 59
Evaluation of prognostic factors for overall survival in patients with chronic myelomonocytic leukemia by different scoring systems: which is the best? 53
Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib 52
Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib. 51
The EUTOS score identifies chronic myeloid leukeamia patients with poor prognosis treated with imatinib first or second line. 49
Imatinib induces body mass changes in women with chronic myeloid leukemia. 48
Direct oral anticoagulants for the treatment of Mondor's disease not responding to low-molecular weight heparin 48
PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count 48
Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia 47
Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants 44
Outcomes of long‐term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis 44
A Multicenter Real-Life Study On Anticoagulant Treatment With Direct Oral Anticoagulants In Patients With Ph Negative Myeloproliferative Neoplasms 44
Hemorrhagic Complications in Patients Treated With Azacitidine and Direct Oral Anticoagulants 41
MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients. 41
Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants (DOACs) in patients with major congenital thrombophilia 40
Adaptive evolution of male accessory gland proteins involved in post-mating reproductive mechanisms of the african malaria mosquito Anopheles gambiae. 40
Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going? 40
Role of Factor V R2 Haplotype and Common Thrombophilia Markers as Genetic Risk Factors for Ischemic Stroke 38
Single centre experience on Acquired Haemophilia A patients: Diagnosis, clinical management and analysis of factors predictive of response and outcome 37
Direct Oral Anticoagulants In Patients With Hematologic Malignancies 36
post filter thromboembolic prophylaxis in vena cava filter carriers 31
Prognostic Features of Myelodysplastic Syndrome Patients Aged < 50 years: Update of a Single Institution Experience. 30
Cancer-associated venous thromboembolism: the Onco-VTE START2 - Registry 30
The treatment of upper extremities deep vein thrombosis related to thoracic outlet syndrome with direct oral anticoagulants 28
Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants: comparison between patients with major congenital thrombophilia versus non-thrombophilic patients 28
Thromboembolic events following mRNA vaccines for COVID 19: a case series 25
Secondary Prophylaxis of Venous Thromboembolism (VTE) with Low Dose Apixaban or Rivaroxaban: Results from a Patient Population with More than 2 Years of Median Follow-up 10
Totale 3.057
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.031
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.031
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020488 0 0 0 0 68 57 97 82 90 39 33 22
2020/2021438 41 34 37 19 25 91 39 36 32 31 32 21
2021/2022569 20 28 59 4 58 29 13 48 42 48 117 103
2022/2023638 100 143 42 61 55 77 17 37 75 3 22 6
2023/2024251 14 42 4 10 17 69 3 12 0 40 20 20
2024/2025194 20 66 29 39 40 0 0 0 0 0 0 0
Totale 3.057